Results 71 to 80 of about 7,464 (222)
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes [PDF]
, 2014 To evaluate the replication capacity and phenotypic susceptibility to dolutegravir and raltegravir of wild-type and raltegravir-resistant HIV-1 strains in several cellular ...
Calvez, V +11 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 3, March 2026.ABSTRACT Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase ...
Alison Luckey +10 more
wiley +1 more source
AIDS Research and Therapy, 2017 Background As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and ...
Marianne Harris +5 more
doaj +1 more source
Drugs in R&D, 2023 Background and Objective Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone.
Nicola Ferri +10 more
doaj +1 more source
Polypharmacy in HIV: Rethinking what counts and why it matters
HIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran +6 more
wiley +1 more source
PLoS ONE, 2015 Some HIV antiretroviral therapies (ART) have been associated with renal toxicities, which become of increasing concern as HIV-infected patients age and develop comorbidities.
Sandrine Cure +5 more
doaj +1 more source
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS [PDF]
, 2015 Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Das, A., Das, S., Taha, H.
core +3 more sources
HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli +11 more
wiley +1 more source
Journal of the International Association of Providers of AIDS Care, 2017 We report the first identified case of suspected iatrogenic adrenal insufficiency after an interlaminar injection of triamcinolone acetonide while on concomitant Stribild (elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg ...
Chanie Wassner PharmD, BCCCP +3 more
doaj +1 more source
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025
HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni +19 more
wiley +1 more source